PMID- 23864251
OWN - NLM
STAT- MEDLINE
DCOM- 20140417
LR  - 20211021
IS  - 1559-131X (Electronic)
IS  - 1357-0560 (Linking)
VI  - 30
IP  - 3
DP  - 2013
TI  - Feasibility and efficacy of combined cisplatin plus irinotecan chemotherapy for 
      gastroenteropancreatic neuroendocrine carcinomas.
PG  - 664
LID - 10.1007/s12032-013-0664-y [doi]
AB  - No standard treatment is currently available for gastroenteropancreatic 
      neuroendocrine carcinomas (GEP-NEC). Therefore, we conducted this study to 
      evaluate the effect of the combination of irinotecan and cisplatin in the 
      treatment of GEP-NECs. Clinical data of 16 locally advanced or metastatic GEP-NEC 
      patients treated with irinotecan plus cisplatin regimen in our center from 
      September 2009 to August 2011 were reviewed. The regimen included 2-week cycles 
      of 180 mg/m(2) irinotecan and 50 mg/m(2) cisplatin on day 1. Median age was 57 
      years. The overall response rate was 57.1%, with a disease control rate of 78.6%. 
      One patient achieved pathologic complete response and underwent esophagectomy 
      after chemotherapy. Two patients who had gotten progressive disease were given 
      sequential octreotide long-acting release (LAR) treatment and got disease 
      progression again within 1 month. Six patients who achieved disease control 
      received octreotide LAR as maintenance treatment. The total number of cycles of 
      octreotide was 41, with a median of 4.5 (3-20 cycles). The progression-free 
      survival was 5.5 months, with overall survival of 10.6 months. Grades 3-4 
      hematological adverse events (AEs) occurred in 10 patients (62.5%) and 3 patients 
      (18.7%) suffered grades 3-4 non-hematological AEs; no patient died of AEs. The 
      irinotecan plus cisplatin chemotherapy is moderately effective and tolerable well 
      tolerated in advanced or metastatic GEP-NEC patients; octreotide LAR may be a 
      good maintenance treatment and should be considered as a treatment option for 
      these patients in the future.
FAU - Lu, Z H
AU  - Lu ZH
AD  - Key Laboratory of Carcinogenesis and Translational Research (Ministry of 
      Education), Department of GI Oncology, Peking University School of Oncology, 
      Beijing Cancer Hospital and Institute, Beijing 100142, China.
FAU - Li, J
AU  - Li J
FAU - Lu, M
AU  - Lu M
FAU - Zhang, X T
AU  - Zhang XT
FAU - Li, J
AU  - Li J
FAU - Zhou, J
AU  - Zhou J
FAU - Wang, X C
AU  - Wang XC
FAU - Gong, J F
AU  - Gong JF
FAU - Gao, J
AU  - Gao J
FAU - Li, Y
AU  - Li Y
FAU - Shen, L
AU  - Shen L
LA  - eng
PT  - Journal Article
DEP - 20130718
PL  - United States
TA  - Med Oncol
JT  - Medical oncology (Northwood, London, England)
JID - 9435512
RN  - 7673326042 (Irinotecan)
RN  - Q20Q21Q62J (Cisplatin)
RN  - XT3Z54Z28A (Camptothecin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use
MH  - Camptothecin/administration & dosage/adverse effects/analogs & derivatives
MH  - Carcinoma, Neuroendocrine/*drug therapy/mortality
MH  - Cisplatin/administration & dosage/adverse effects
MH  - Disease Progression
MH  - Disease-Free Survival
MH  - Female
MH  - Humans
MH  - Irinotecan
MH  - Male
MH  - Middle Aged
EDAT- 2013/07/19 06:00
MHDA- 2014/04/18 06:00
CRDT- 2013/07/19 06:00
PHST- 2013/06/14 00:00 [received]
PHST- 2013/07/09 00:00 [accepted]
PHST- 2013/07/19 06:00 [entrez]
PHST- 2013/07/19 06:00 [pubmed]
PHST- 2014/04/18 06:00 [medline]
AID - 10.1007/s12032-013-0664-y [doi]
PST - ppublish
SO  - Med Oncol. 2013;30(3):664. doi: 10.1007/s12032-013-0664-y. Epub 2013 Jul 18.